December 16, 2022

Dear Colleagues,

Two decades ago, I was visiting Japan in late November. It was impossible not to notice the lavish Christmas decorations. What was notable was that it was a full month before Christmas and Japan is largely a non-Christian country. I asked one of my hosts about the red and green ornaments and snowy Christmas scenes and was informed that in Japan they like to celebrate ALL holidays. The concept stuck with me.

Now in the middle of December, we have many holiday choices. Whatever holidays you officially celebrate—none, one, or more—this is a time to take a little time off, relax, smile more easily, and spend time with those you love. It is also a time to be reflective and whenever possible, to be grateful.

Personally, as I have said before, I am enormously grateful for Nancy’s and my move to New Haven, for the great potential we have at Yale, and for my colleagues. I was recently at the San Antonio Breast Cancer Symposium with many of my former mentees and colleagues. While I enjoyed seeing them and they will remain a part of my life, I realized that I have a new home and a remarkable group of colleagues and friends to work with, to support, and to enjoy.

Thank you for all that you do every day. Having a mission in life is critical, and whether your passion is clinical care, research, administration, education, or some combination, what you do brings us closer to a time when cancer is no longer a burden on individuals and for our society. Please rejoice in what you do for Yale, for our patients, for research, for each other, and for our future.

Happy Holidays! I look forward to the New Year with great optimism.

Eric

Announcements

Dean Brown to Present State of the School on Tuesday
Please join us on Tuesday, December 20 at noon in the Park Street Auditorium at 55 Park Street for a presentation by Nancy Brown, MD, Jean and David W. Wallace Dean of the Yale School of Medicine and C.N.H. Long Professor of Internal Medicine on the State of the School. Please send questions for Dean Brown in advance by email to:

Eric P. Winer, MD
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Network

Yale New Haven Health
Smilow Cancer Hospital

News Center

Why Some Lung Tumors Respond Better to Targeted Therapies Than Others

Opinion: The Deadly Consequences for
questions for Dean Brown in advance by email to canceranswers@yale.edu. There will also be an opportunity to ask questions during the program.

Rong Fan, PhD, Appointed the Harold D. Hodgkinson Professor of Biomedical Engineering
We are pleased to announce Rong Fan, PhD, a member of the Yale Cancer Center Cancer Signaling Networks Research Programs, has been appointed the Harold D. Hodgkinson Professor of Biomedical Engineering at Yale University. Dr. Fan has led research making significant contributions to biotechnology innovation and precision medicine, particularly in the field of single-cell & spatial omics and cancer immunotherapy. He is also a Professor of Pathology at Yale School of Medicine.

Since joining Yale in 2010, Dr. Fan has invented multiple innovative and transformative technologies in single-cell and spatial omics analysis and demonstrated a unique talent for inventing new technologies to advance human genomics and precision medicine. His inventions have led to the creation of three companies. In addition, Dr. Fan is an enthusiastic and valued mentor to young inventors. His graduate students and postdocs are frequently co-inventors on patent applications. He received a BS and MS from the University of Science and Technology of China, and his PhD from the University of California, Berkeley.

Steven H. Kleinstein, PhD, Appointed Anthony N. Brady Professor of Pathology
Congratulations to Dr. Steven H. Kleinstein, a member of Yale Cancer Center’s Cancer Immunology Research Program, on his appointment as the Anthony N. Brady Professor of Pathology. Dr. Kleinstein has made fundamental contributions to immunology through the development and application of innovative computational methods. He also serves as co-director of graduate studies for the Program in Computational Biology and Bioinformatics.

A longstanding focus of Dr. Kleinstein’s work has been somatic hypermutation (SHM) and B cell affinity maturation, the core of adaptive immunity. His lab developed the widely used Immcantation framework, which is based on foundational computational methods he devised, including the identification of clonally related B cells, integration of the resulting lineages, detection of immune selection, and inference of migration/differentiation networks. Dr. Kleinstein has applied these methods in collaborative studies to gain important biological insights into human infection, vaccination, and autoimmunity. He completed his PhD in computer science at Princeton University and joined the faculty of the Department of Pathology in 2006; he
University and joined the faculty of the Department of Pathology in 2006; he has a secondary appointment in the Department of Immunobiology.

Notables

Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology, Vice Chair for Translational Research, Therapeutic Radiology, and Scientific Director, Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center, has been named the 2022 BioCT Entrepreneur of the Year. The Entrepreneur of the Year award was established by BioCT to acknowledge the importance of showcasing unique accomplishments of entrepreneurs in the Connecticut community whose accomplishments are also having impact beyond the borders of the state.

Edward Perry, Jr., MD, Assistant Professor of Medicine (Medical Oncology), recently presented the keynote lecture on "Schwartz Rounds at VA Connecticut Healthcare System" at the Association of VA Hematology/Oncology Annual Meeting in San Diego.

Laura J. Morrison, MD, Associate Professor of Medicine (Geriatrics), Director of Palliative Medicine Education, and Director, Yale Hospice and Palliative Medicine Fellowship, was invited to participate as Core Faculty for the TalkVermont Advanced Goals of Care Communication Skills Course in Burlington, Vermont. This new, innovative course was designed specifically for palliative care physician and APRN fellows from University of Vermont, Dartmouth, Maine Medical, and Yale to train together in advanced serious illness communication simulation scenarios.

Mathieu Bakhoum, MD, PhD, Assistant Professor of Ophthalmology & Visual Science, has received a grant from the Connecticut Lions Eye Research Foundation (CLERF). The funding will support his laboratory's efforts to develop non-invasive biomarkers for uveal melanoma, the most common intraocular cancer in adults.

Bayan Galal '23, a pre-med student double majoring in molecular, cellular, and developmental biology and global affairs studying in the laboratory of Daniel DiMaio, MD, PhD, has been named a Marshall Scholar, one of only 40 in the country. Marshall Scholarships fund up to three years of graduate study in the United Kingdom for Americans poised to become leaders in their fields.

Diversity, Equity, and Inclusion

First-Generation Low-Income Faculty Mentors
We are seeking self-identified first-generation low-income (FGLI) faculty members at Yale School of Medicine who are interested in receiving and/or providing medical career mentorship.

First-generation low-income (FGLI) individuals in medicine are believed to encounter a unique set of obstacles to their career progression. In an effort to create community, and provide support, networking, and mentoring opportunities, we are reaching out to assess interest in a Yale FGLI
opportunities, we are reaching out to assess interest in a Yale FGLI Mentorship Program among our Yale School of Medicine faculty.

Who are first-generation low-income individuals in medicine?

- A "first-generation" individual in medicine is a physician whose parents have not attended or graduated from college thus making them among the first generation in their family to earn a bachelor's degree, or a physician who is a first-generation American or an immigrant to the United States.
- An individual in medicine who was formerly a "low-income student" is a physician who identifies with having been raised in a low socioeconomic environment. It is sometimes defined in higher education forums by Pell Grant eligibility as an undergraduate student and/or U.S. Department of Health and Human Services Scholarship for Disadvantaged Students eligibility as a medical student.
- Individuals in medicine who are formerly "first-generation low-income (FGLI) students" are physicians who identify with having been either or both a "first-generation" and/or "low-income" student.

If you are interested in learning more about receiving or providing mentorship as a FGLI faculty member, please complete a brief survey. If you do not identify as a FGL faculty member but would like to mentor FGLI individuals in medicine, please also complete the survey and indicate so. We will then be in touch with additional information.

Expanded Fertility Benefits at Yale

As of 2023, fertility benefits for Yale faculty and non-union employees who are enrolled in Aetna or Yale Health medical benefits will expand to single individuals and those with single-sex partners. Additionally, a surrogacy benefit ($10K toward authorized costs) is available to any benefit-eligible employee. While there is still work to be done to advocate for fertility benefits for all members of the Yale University community, this is positive progress. Please review your individual benefits and reach out to your plan contact for more information.

Employee Profile: Barbara Lumpkin

After over 30 years at Yale, Barbara Lumpkin, Senior Administrative Assistant for Yale Cancer Center, will retire as of next week. Barbara started as part of the former Cancer Information Service (CIS), a cancer communication network for the National Cancer Institute, but moved to the Section of Hematology where she was supporting five faculty/clinicians.

In between her daily tasks of scheduling meetings, submitting expense reports, and making travel arrangements, Barbara has grown a great appreciation for the dedication and commitment it takes to manage both the Cancer Center and its patients.
appreciation for the dedication and commitment it takes to manage both the clinical and academic responsibilities that her faculty take on, and has been honored to play a role in assisting with that. "There is so much work done outside of the clinic that people don't realize. They are required to take certain classes, give lectures, and stay up to date on the latest advances. I am so proud to have been a part of this organization for so long, and to support these doctors that are making a difference."

Richard Carr, Administrative Supervisor for the Section of Hematology, commented, "Yale Cancer Center has been fortunate to have Barbara's support now for 32 years. She has worked with kindness, dedication, and as a team player. I am especially appreciative of her work this past year, having continued supporting hematology until a replacement could be found, and then filling in where there was need these last months. I am truly grateful to her for staying on with us for a little longer."

Alfred Lee, MD, PhD, Associate Professor of Medicine (Hematology), commented, "Barbara has been my administrative assistant since I started at Yale and she first helped me get settled. Since then, she's been with me every step of the way, helping me out academically, administratively, and even emotionally. She is one of the dearest people in my life and has become family to me. I will miss her support greatly."

Thank you to Barbara. We send her congratulations, appreciation, and best wishes on her next chapter.

Recent Publications

Agashe, R. P., Lippman, S. M., & Kurzrock, R.
Read More

Yan, H., Talty, R., & Johnson, C. H.
Read More

Shabbir, A., Kojadinovic, A., Shafiq, T., & Mundi, P. S.
Read More

Goshua, G., Bendapudi, P. K., & Lee, A. I.
Read More

Fluid shear stress enhances proliferation of breast cancer cells via downregulation of the c-subunit of the F1FO ATP synthase.
Read More
As the new director of the Sickle Cell Program at Smilow Cancer Hospital, Cecelia “Cece” Calhoun, MD, MPH, MBA, strives to ease the suffering and burden of sickle cell warriors and advance their care options by building on the program’s strong foundation and rallying the tremendous resources of Yale; but most importantly, the knowledge of the community.

Recently on Yale Cancer Answers, our new Chief of Surgical Oncology at Smilow Cancer Hospital and Yale Cancer Center, Dr. Kiran Turaga, discussed innovations in the treatment of metastatic cancers. Listen on Connecticut Public Radio or download our podcast from iTunes.
Meet Mehra Golshan, MD, MBA, Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Executive Vice Chair of Surgery. “I am grateful for the privilege of working with an amazing team of nurses, staff, advanced practice providers, physicians in the care of our cancer patients across the state of CT and beyond. Yale Cancer Center/Smilow provides a lifeline during a patient and their families most desperate hour, something that we never forget day in and day out.”

The Lustgarten Foundation announced Mandar Muzumdar, MD, Assistant Professor of Genetics and of Medicine (Medical Oncology), as the recipient of a 2022 Innovation and Collaboration Program Grant. The funding will support his study titled “Dietary oleic acid reprograms pancreatic lipid metabolism to drive cancer development.” Congratulations, Dr. Muzumdar!

**Cassidy, R. N., Tidey, J. W., Jackson, K. M., Cioe, P. A., Murphy, S. E., Krishnan-Sarin, S., Hatsukami, D., & Colby, S. M.**

The Impact of Reducing Nicotine Content on Adolescent Cigarette Smoking and Nicotine Exposure: Results from a Randomized Controlled Trial. *Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco*, ntac279.


Defining morphologic features of invasion in pulmonary non-mucinous adenocarcinoma with lepidic growth - A proposal by the IASLC Pathology Committee. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer*, S1556-0864(22)01936-0.

**Bold, K., O'Malley, S., Krishnan-Sarin, S., & Morean, M.**


Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. *Annals of oncology: official journal of the European Society for Medical Oncology*, S0923-7534(22)04760-3.


**Xi, Q., Meza, R., Leventhal, A., & Tam, J.**

Funding and Award Opportunities

Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)
Through this FOA, the NCI invites P20 planning grant applications for developing collaborative partnerships between institutions serving health disparity populations and underrepresented students (ISUPSSs) and NCI-designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education.
Application Deadline: January 6, 2023
Read More

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)
This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity populations and underrepresented students and NCI-designated Cancer Centers. The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education, and practice.
Read More
and address challenges in cancer and cancer disparities research, education, and outreach, as well as cancer's impact on underserved populations.

**Application Deadline:** January 6, 2023

**Read More**

### Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)

Through this FOA, the NCI invites P20 planning grant applications for developing collaborative partnerships between institutions serving health disparity populations and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education.

**Application Deadline:** January 6, 2023

**Read More**

### DeLuca Pilot Award

5 pilot awards will be awarded to support investigators pursuing research in Hematology and to generate preliminary data for new NCI/NIH grant applications. The research should seek to advance our knowledge in Hematologic disorders and to improve patient care, therapies, and outcomes. For more information, please contact Richard.Carr@yale.edu

**Letter of Intent Due:** January 9, 2023

**Read More**

### Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01/U24)

The purpose of this FOA is to solicit applications for Liquid Biopsy Research Laboratories (LBRLs), one of the two components of the Precompetitive Collaboration on Liquid Biopsy for Early-Cancer Assessment Consortium (LBC). The LBRLs will conduct research on the development of liquid biopsy technologies, assays and/or methods for the capture and analysis of tumor associated cells, DNA, RNA, or exosomes in body fluids of individuals with early-stage cancer or at high risk of developing the disease.

**Application Deadline:** January 10, 2023

**Read More**

### CRI Lloyd J. Old STAR Program

The CRI Lloyd J. Old STAR Program—Scientists TAking Risks—provides long-term funding to mid-career scientists, giving them the freedom and flexibility to pursue high-risk, high-reward research at the forefront of discovery and innovation in cancer immunotherapy.

**Deadline for Applications:** January 15, 2023

**Read More**

### Breast Cancer Research Foundation Precision Prevention Initiative

The overarching goal of the 2023 BCRF Precision Prevention Initiative is to fuel innovation and accelerate breast cancer prevention research by challenging the research community to think boldly; to explore multidisciplinary approaches to get the answers in less time, utilize new technologies or identify new ways to examine available data, and to build or enhance infrastructure, resources, and tools that will facilitate innovation in prevention research for years to come.

**Letter of Intent Due:** January 16, 2023

**Read More**

---

**Calendar**

### Yale Cancer Answers

**December 18; 7:30 PM**

**Physical Therapy Support for Patients**

Scott Capozza, PT, MS, and Suzanne Burbank, PT

**Learn More**

### Yale Cancer Center Special Seminar

---
Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01)
The purpose of this FOA is to support research that will advance the measurement and methodology of complex constructs relevant to minority health and health disparities.
**Application Deadline:** February 5, 2023
Read More

NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01)
This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups are encouraged to work with their institutions to apply.
**Application Deadline:** February 6, 2024
Read More

Transformative Educational Advancement and Mentoring Network (TEAM) (R25)
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
**Application Deadline:** February 10, 2023
Read More

2023 K12 Immuno-Oncology Training Program (IOTP) Scholar Award
YCC-IOTP Scholar Award is an award for junior faculty to enhance research skills beyond the training provided during graduate and postgraduate training. Successful applicants are required to demonstrate a strong commitment to a career in cancer immunology. The two-year IOTP curriculum includes didactic and practical training in basic, translational and clinical aspects of cancer immunology research. The program also includes a required research component (either clinical or bench research, or a combination thereof). Applicants are required to identify a mentor and a provide a research and mentorship proposal.
**Full Application Due:** February 15, 2023
Read More

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01)
The purpose of this FOA is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence.
**Application Deadline:** February 21, 2023
Read More

---

**Yale Cancer Center Special Seminar**
December 20; 9:30 AM
*Cancer Immunotherapy in Modern Medicine - Immune Check Point Inhibitor Related Gastrointestinal Toxicities and Future Directives*
Binny Khandakar
Learn More

**Yale Cancer Center Grand Rounds**
December 20; 12:00 PM
55 Park Street; Auditorium
*State of the School*
Nancy J. Brown, MD
Learn More

**Cancer Genetics and Prevention Program Seminar**
December 22; 2:30 PM
Learn More

**Yale Cancer Answers**
December 25; 7:30 PM
*Theranostics and clinical trials for GI Cancers*
Gabriela Zagarodone Spilberg Missine, MD
Learn More

**Yale Cancer Answers**
January 1; 7:30 PM
*Racial Disparities and Cancer and Improving Health Outcomes*
Jacquelyne Gaddy
Learn More

---

**Share your news!**
Please submit your recent publications, awards, and grant announcements to:

**Renee Gaudette**
Director, Public Affairs and Communications
Pathway to Independence Award in Tobacco Regulatory Research (K99/R00)
The purpose of this FOA is to increase and maintain a strong cohort of new
and talented independent investigators conducting research that will inform
the development and evaluation of regulations on tobacco product
manufacturing, distribution, and marketing.
**Application Deadline:** February 21, 2023
Read More

NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025
This FOA supports small research projects on cancer that can be carried out in
a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
**Application Deadline:** February 22, 2023
Read More

NCI Cancer Screening Research Network Funding Opportunities
The CSRN conducts rigorous, multi-center cancer screening trials and studies with large and diverse populations in a variety of health care settings with the goal of reducing cancer incidence and cancer-related morbidity and mortality. Cancer screening provides a unique opportunity to diagnose cancers and pre-cancerous lesions before symptoms develop.
- **ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1)**
Read More
- Statistics and Data Management Center (UG1)
Read More
- Coordinating and Communication Center (UG1)
Read More
**Application Deadlines:** February 28, 2023

JH Milstone Fund Grant
JH Milstone Fund will award a grant in 2023 to support early-stage investigators and innovative research that improves understanding of bleeding, thrombosis or thrombolysis. The research can focus on the genetics, biochemistry or cell biology of coagulation or thrombolysis or on the causes, pathogenesis, diagnosis or treatment of bleeding and clotting disorders. In the absence of preliminary data, appropriate mentors and/or collaborators are important. For more information, please contact Richard.Carr@yale.edu
**Letter of Intent Due:** March 1, 2023
Read More

DeLuca Career Development Award
The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the goal to achieve independent support for their research from a national agency. For more information, please contact Richard.Carr@yale.edu
**Letter of Intent Due:** March 1, 2023
Read More

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61)
Clinical Cancer Research (R61)
This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

**Application Deadline:** March 1, 2023

Read More

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)
This FOA invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community.

**Application Deadline:** March 1, 2023

Read More

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61)
This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

**Application Deadline:** March 1, 2023

Read More

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)
This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

**Application Deadline:** March 1, 2023

Read More

YCCI Educational Funding Support Opportunities
- **YCCI Scholar Awards** and **Yale Physician-Scientist Development Awards**: provide salary and/or research funds to a select number of junior faculty members who are strongly committed to research careers focused on improving human health.

**Letters of Intent Due:** January 6, 2023

Read More
YCCI Multidisciplinary Post-Doctoral Training Program in Translational Research: provide an opportunity for Yale post-doctoral trainees in the Schools of Medicine, Nursing, Public Health, Engineering and Applied Science or other appropriate Departments in the Graduate School to receive up to 2 years devoted to training across the full span of clinical and translational research focused on human health.

Application Deadline: March 10, 2023

Read More

YCCI Multidisciplinary Pre-Doctoral Training Program in Translational Research: aims to identify and support a representative and diverse group of outstanding trainees who specifically want to pursue careers in clinical and translational research; to train them in the use of state-of-the-art research tools; to enhance their abilities to work collaboratively in complex multidisciplinary research teams; to provide outstanding mentoring (including concordant mentoring) by experienced and diverse faculty that support the trainee’s long-term professional development.

Application Deadline: March 10, 2023

Read More

AHEAD (Advancing Head and Neck Cancer Early Detection Research) (U01)
The goal of this FOA is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This initiative will encourage development, evaluation, and validation of biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early HNC.

Application Deadline: March 14, 2023

Read More

Diversity and Inclusion in Breast Cancer Research
The following research awards are designed with the primary goal of increasing diversity in the oncology workforce and breast cancer research. These awards are made possible through the support of the Breast Cancer Research Foundation (BCRF).

- Career Development Award: Full Application Due: March 13, 2023

Read More
- Young Investigator Award: Full Application Due: March 13, 2023

Read More

Joint SPORE Developmental Research Program (DRP) Award – Cancer Disparities
The YCC Translational Research Office in collaboration with the Yale SPORE in Lung Cancer (YSILC) and the Yale Head and Neck SPORE (YHN-SPORE) have launched a new DRP award to provide support up to $50,000 for a translational pilot project focused on disparities-related cancer research in the field of Head and Neck and/or Lung cancer. Studies with a strong translational or clinical component that have the potential to evolve into, or be incorporated into, a full SPORE project and projects with multi-disciplinary collaborations and/or community-based participatory research studies are encouraged.

We encourage to submit your letter of intent (LOI) to anna.arnal@yale.edu
There is no deadline to apply, LOIs will be reviewed and eligible applicants will be invited to submit a full application online at: https://yale.infoready4.com/

Read More